Literature DB >> 8543795

B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.

T F Gajewski1.   

Abstract

We recently have developed a method to generate primary P815-specific CTL in vitro from normal syngeneic splenocytes by employing transfection of B7-1 combined with exogenous IL-12 and IL-6. Surprisingly, when the homologous costimulator molecule B7-2 was substituted for B7-1 in this system, no specific CTL activity was obtained. Similarly, B7-1- but not B7-2-transfected P815 cells generated alloantigen-specific CTL activity from C57BL/6, accessory cell- and CD4(+)-depleted splenocytes, and costimulated proliferation of CD8+ lymphocytes in the presence of low doses of anti-CD3 mAb. In all systems, combined expression of both B7-1 and B7-2 costimulated as effectively as B7-1 alone, arguing against delivery of a dominant negative signal by B7-2. Proliferation of allogeneic, CD4(+)-depleted splenocytes in response to P815 cells, which relies on costimulation by normal accessory cells, was inhibited by anti-B7-1 but not anti-B7-2 mAbs. Finally, indirect evidence suggested a higher avidity of B7-1+ cells than B7-2+ cells for CTLA4. Thus, at least in the context of primary stimulation by irradiated P815 transfectants, B7-1 appears to be superior to B7-2 at costimulation of CD8+ T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  B7 costimulation is critical for antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus.

Authors:  A J McAdam; E A Farkash; B E Gewurz; A H Sharpe
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules.

Authors:  Sharmila S Pejawar; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 3.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 5.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

6.  Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Authors:  Hiroko Kobori; Masaaki Hashiguchi; Jinhua Piao; Moriyuki Kato; Patcharee Ritprajak; Miyuki Azuma
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

Review 7.  T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

Authors:  Joel Crespo; Haoyu Sun; Theodore H Welling; Zhigang Tian; Weiping Zou
Journal:  Curr Opin Immunol       Date:  2013-01-06       Impact factor: 7.486

8.  Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.

Authors:  B M Pützer; M Hitt; W J Muller; P Emtage; J Gauldie; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

9.  n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids.

Authors:  G A Böhmig; P M Krieger; M D Säemann; C Wenhardt; E Pohanka; G J Zlabinger
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

10.  Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Ramon Arens; Rachel Flynn; Alessandro Sette; Stephen P Schoenberger; Michael Croft
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.